Images List Premium Download Classic

Immunostimulator

Immunostimulator-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Chemical modification of short small hairpin rnas for inhibition of gene expression
Somagenics, Inc.
May 31, 2018 - N°20180148723

Aspects of the present invention include the production and use of chemically modified rnai agents (e.g., shrnas) in gene silencing applications. The chemically modified rnai agents disclosed herein have reduced immunostimulatory activity, increased serum stability, or both, as compared to a corresponding rnai agent not having the chemical modification.
Method of stimulating tlr9-activated immune response
National Health Research Institutes
May 17, 2018 - N°20180135053

A method of stimulating a tlr9-activated immune response or enhancing a tlr9-activated immune response to an antigen is disclosed herein. Tlr9 is the cellular receptor for cpg-odn, and current developed cpg-odn has low activity to rabbit tlr9.
Immunostimulatory compositions, particles, and uses related thereto
Emory University
May 03, 2018 - N°20180117145

In some embodiments, described herein is a method of tumor treatment or tumor vaccination. The method generally comprises applying to a human being in need thereof a tumor therapeutic composition or tumor vaccine defined herein.
Immunostimulator Patent Pack
Download + patent application PDFs
Immunostimulator Patent Applications
Download + Immunostimulator-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Immunostimulator-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
E. R. Squibb & Sons, L.l.c.
March 08, 2018 - N°20180066054

The present disclosure provides isolated monoclonal antibodies that specifically bind to lag-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human lag-3.
Lipid a mimics, methods of preparation, and uses thereof
Immunovaccine Technologies Inc.
January 11, 2018 - N°20180009833

The invention provides lipid a mimics in which one or both of the sugar residues of a natural lipid a disaccharide backbone has been replaced with an aromatic group. These lipid a mimics may further differ from a natural lipid a molecule with respect to other structural characteristics, such as, a different number of phosphate groups present, changes in the ...
Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity
New York University
January 04, 2018 - N°20180000912

Provided are polynucleotides and viral vectors, particularly, alphavirus vectors such as sindbis viral vectors, which encode multiple, e.g., two or more, epitopes of at least one tumor associated antigen in which each epitope is separated by a processing or enzyme cleavage site. The multiple epitopes of the two or more tumor associated antigens encoded by the described polynucleotides and ...
Immunostimulator Patent Pack
Download + patent application PDFs
Immunostimulator Patent Applications
Download + Immunostimulator-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Immunostimulator-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Non-aggregating immunostimulatory oligonucleotides
Genedesign, Inc.
December 21, 2017 - N°20170362591

Provided are non-aggregating immunostimulatory oligonucleotides. The present invention also provides a delivery agent for an immunostimulatory-oligonucleotide nucleic acid medicine, said delivery agent including a nucleic acid that contains a phosphorothioated nucleotide.
Bromodomain inhibitor as adjuvant in cancer immunotherapy
Dana-farber Cancer Institute, Inc.
December 21, 2017 - N°20170360801

Inhibition of bromodomain proteins in antigen presenting cells is shown herein to be more inflammatory, to display lower expression of the immunosuppressive molecule pdl1, and to be capable of restoring the responsiveness of tolerant t-cells. Therefore, disclosed is a method for promoting t-cell activation during cancer immunotherapy in a subject that involves administering to a subject undergoing cancer immunotherapy a ...
Compositions and methods for self-adjuvanting vaccines against microbes and tumors
The Regents Of The University Of California
November 09, 2017 - N°20170319685

The present invention is drawn to compositions and methods to enhance an immune response in order to prevent or treat infections or hyperproliferative diseases such as cancer. More particularly, the composition is an immunostimulatory intracellular signaling peptide fused directly or indirectly to a peptide that leads to multimerization into complexes of three or more units, where the intracellular signaling peptide ...
Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
The Texas A&m University System
November 09, 2017 - N°20170319671

Vaccine compositions including a yeast comprising an immunostimulatory polypeptide and optionally an antigenic polypeptide are provided herein. The immunostimulatory polypeptide and the antigenic polypeptide are expressed or displayed on the surface of the yeast vaccine composition.
New immunostimulatory compounds
October 19, 2017 - N°20170298083

The present invention relates to novel immunostimulatory molecules which are derived from the intestinal protozoan entamoeba histolytica. The compounds have been found to be useful for enhancing and/or inducing an immune response in a subject in need thereof.
Treatment of cancers with immunostimulatory hiv tat derivative polypeptides
Pin Pharma, Inc.
September 28, 2017 - N°20170274040

Disclosed herein are compositions comprising a human immunodeficiency virus (hiv) trans-activator of transcription (tat) derivative polypeptide with increased immunostimulatory properties relative to the native tat polypeptide, pharmaceutical compositions comprising the tat derivative polypeptide, and methods of treating cancer using the tat derivative polypeptide.. .
Modulating agonistic tnfr antibodies
The Rockefeller University
August 31, 2017 - N°20170247463

The instant invention relates to agents (e.g., agonistic antibodies) able to stimulate the immune system of a mammalian animal and activate target-cell specific t lymphocyte responses. Such agents may be identified based on the ability to engage a receptor from the tnfr superfamily and thereby mimic the natural ligand for the receptor from the tnfr superfamily.
Immunostimulator Patent Pack
Download + patent application PDFs
Immunostimulator Patent Applications
Download + Immunostimulator-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Immunostimulator-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Smc combination therapy for the treatment of cancer
Children's Hospital Of Eastern Ontario Research Institute Inc.
August 24, 2017 - N°20170239347

The present invention includes methods and compositions for enhancing the efficacy of smcs in the treatment of cancer. In particular, the present invention includes methods and compositions for combination therapies that include an smc and at least a second agent that stimulates one or more apoptotic or immune pathways.
System and method for the detection and treatment of infection by a microbial agent associated ...
August 24, 2017 - N°20170239278

A method of treating a patient, comprising administering at least one antibiotic, e.g., doxycycline and ciprofloxacin, sufficient to substantially treat an intracellular bacterial organism present in at least erythrocytes, e.g., over a course of at least two weeks; and subsequently administering at least one immunostimulant, e.g., which directly or indirectly increases levels of immunostimulatory cytokines in the ...
Tumor antigen specific antibodies and tlr3 stimulation to enhance the performance of checkpoint interference therapy ...
Oncoquest Inc.
August 10, 2017 - N°20170226221

The present disclosure relates to a method for inhibiting cancer tumor growth in a patient by administering to the patient a therapeutic monoclonal antibody specific for a tumor associated antigen in combination with at least one immunostimulatory compound, and at least one immune homeostatic checkpoint inhibitor. Also disclosed are uses, compositions and kits thereof..
Immunogenic lhrh composition and use thereof in pigs
United Biomedical, Inc.
August 03, 2017 - N°20170216418

A vaccine composition for castrating pigs, comprising a peptide immunogen and a veterinarily acceptable delivery vehicle or adjuvant, wherein the peptide immunogen comprises (a) a lhrh peptide of seq id no: 1, and (b) at least one t helper epitope selected from a group consisting of seq id nos: 2, 3, 4, and 5, and, optionally, an immunostimulatory peptide of seq in no: 6, wherein the ...
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an ...
Curevac Ag
July 20, 2017 - N°20170202957

The present invention relates to an immunostimulatory composition comprising a) an adjuvant component, comprising or consisting of at least one (m)rna, complexed with a cationic or polycationic compound, and b) at least one free mrna, encoding at least one therapeutically active protein, antigen, allergen and/or antibody, wherein the immunostimulatory composition is capable to elicit or enhance an innate ...
Immunostimulator and method for producing the same
Sysmex Corporation
June 29, 2017 - N°20170182157

Disclosed is an immunostimulator containing virus-like particles, in which the virus-like particles contain an outer coat protein containing an amino acid sequence selected from the group consisting of seq id no. 1, seq id no.
Immunostimulatory combinations of tlr ligands and methods of use
The United States Of America, As Represented By The Secretary, Department Of Health & Human Servic
June 15, 2017 - N°20170165359

The present invention provides immunostimulatory combinations of tlr ligands and therapeutic and/or prophylactic methods that include administering an immunostimulatory combination to a subject. In general, the immunostimulatory combinations described herein can provide an increased immune response compared to other immunostimulatory combinations and/or compositions..
Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof
University Of Southampton
June 08, 2017 - N°20170158771

Through a combination of in vitro and in vivo approaches, the inventors show that human igg2 (h2) delivers unique fcγr-independent agonistic activity to anti-cd40 antibodies and to antibodies specific to other immunostimulatory receptors, including 4-1bb and cd28. Investigation of an anti-human cd40 mab, lob7.4, revealed that the unique activity of h2 was dependent upon the precise ...
Loading